EA
HRTX icon

Emerald Advisers’s Heron Therapeutics HRTX Stock Holding History

Emerald Advisers’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-10,350
Closed -$104K – 347
2014
Q4 		$104K Sell
10,350
-295,550
-97% -$2.41M 0.01% 333
2014
Q3 		$2.55M Buy
305,900
+22,050
+8% +$205K 0.15% 183
2014
Q2 		$3.5M Buy
+283,850
New +$3.39M 0.2% 156

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Emerald Advisers's HRTX Position: Q1 2015 in Review

Emerald Advisers sold out of Heron Therapeutics (HRTX) in Q1 2015, closing a stake of 10,350 shares — an estimated $104K sold.

Emerald Advisers first reported a position in HRTX in Q2 2014 and held it in 3 quarters. The position peaked at $3.5M in Q2 2014. 69 funds tracked by Wall St. Rank hold HRTX as of Q1 2015.

  • Emerald Advisers reported no remaining Heron Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Emerald Advisers sold 10,350 Heron Therapeutics shares in Q1 2015, an estimated $104K.
  • Emerald Advisers first reported a position in Heron Therapeutics in Q2 2014 and held it in 3 quarters.
  • Emerald Advisers's Heron Therapeutics position peaked at $3.5M in Q2 2014.
  • 69 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2015.

Based on Emerald Advisers's 13F filing for Q1 2015, filed 29 Apr 2015.